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To Frans and Vera 
“The information I was able to find on the internet about the effects of 
hormones on the workings of the psyche left an impression of confusion and 
incoherence  . . . serotonin was linked to self-esteem, to the sense of recognition 
obtained from the group. But in any case, it was essentially produced in the 
intestine, and it had been found to exist in a great variety of living creatures, 
including amoebas. What feeling of self-esteem could exist among amoebas? 
What sense of recognition from the group? I gradually reached the conclusion 
that medical art remained confused and imprecise about these matters, and that 
antidepressants were among the many medications that work (or don’t) without 
















Excerpt from Serotonin (2019). By Michel Houellebecq. 










The involvement of monoamine neurotransmission in the pathophysiology of depression was 
established already in the 1960s. However despite an abundance of research, the exact role of 
the serotonin (5-HT) and dopamine systems in depression have remained elusive. 
Positron emission tomography (PET) is a nuclear imaging technique that makes the study of 
the living human brain possible at a molecular level. In this thesis, PET methods were 
validated (study I) and applied to study aspects of the serotonin and dopamine systems in 
depression. This was done through patient and control comparisons (study II and III), through 
examining correlations between key 5-HT proteins (study IV), and through a longitudinal 
approach testing patients before and after treatments with known efficacy (study II and III). 
In study I, binding characteristics of the D2 dopamine receptor (D2R) radioligand 
[
11
C]raclopride was evaluated in brain regions where D2R density is low (i.e., outside 
striatum). In most extrastriatal brain regions, little or no decrease in binding was observed 
after administration of a pharmacological competitor, lending no support for valid 
quantification. Further, extrastriatal test-retest repeatability was poor. The results indicate that 
[
11
C]raclopride PET is not suitable for D2R quantification in extrastriatal brain regions. 
The aim of study II was to investigate D2R availability in patients with severe depression, 
compared with healthy controls at baseline and before and after electroconvulsive treatment. 
Nine patients hospitalized for depression were examined using [
11
C]raclopride PET before 
and after a series of electroconvulsive therapy treatments, and nine healthy, matched controls 
were examined twice. Lower striatal D2R availability was observed in patients compared with 
controls. No significant change in [
11
C]raclopride binding was observed in the patient group 
following treatment. The results suggest that low D2R is associated with severe depression. 
In Study III, [
11
C]MADAM PET was used to quantify the 5-HT transporter (5-HTT) in 17 
patients with depression before and after treatment with cognitive behavioral therapy. 
Matched healthy controls were examined once with [
11
C]MADAM PET. Depression severity 
decreased and 5-HTT availability increased significantly in patients following the treatment. 
No significant difference in [
11
C]MADAM binding was observed between controls and 
patients at baseline. The results indicate that previous findings of 5-HT dysregulation in 
patients with depression reflect a temporary state rather than a permanent trait. 
The aim of study IV was to evaluate the correlation between 5-HTT availability and 5-HT 1B 





PET was used to quantify 5-HTT and 5-HT1B respectively. 17 healthy individuals were 
examined with both radioligands. Strong correlations were observed in cortical regions while 
very weak correlations were observed in most subcortical regions. The results could be 
indicative of a strong transsynaptic regulation of the 5-HT system in cortical regions. 
However, the analysis was exploratory and [
11
C]MADAM signal to noise ratio is poor in 
cortex so the results should be interpreted with caution.  
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1.1 RATIONALE FOR THIS THESIS 
The history of psychopharmacology is to a large part a history of serendipity findings. In a 
somewhat circular argumentation, these chance findings have then laid the foundation on 
which the dominant biological explanations for many psychiatric diseases rest. For 
depression, the monoamine hypothesis followed the discovery that pharmacological agents 
increasing cerebral monoamine levels alleviate depressive symptoms
1,2
. Since this theory 
gained popularity in the 1960s, much research has been directed towards the monoamines, 
mainly serotonin, but also dopamine. However, despite solidifying the fact that monoamine 
neurotransmission is important in the pathophysiology of depression, the exact role of these 
neurotransmitters remains elusive. The original idea of low monoamine levels as the root 
cause of depressive symptoms is now considered too simplistic.
3
 Among the evidence 
indicating a more complex biology is the fact that more than 30% of patients with depression 
fail to respond to existing pharmacological treatments inhibiting monoamine reuptake
4
. As 
such, there is a great need for new methods and improved study designs to shed light on the 
role of monoamines in depression, with the end goal of finding better treatment options. 
The nuclear imaging methodology positron emission tomography (PET) allows the study of 
biology at a molecular level in the living human brain. PET brain research is a living field in 
which methods continuously are being developed creating ways to study biological systems 
previously unavailable for in vivo research. 
Longitudinal studies – where patients are examined when depressed and after treatment – 
offer a way to differentiate between “state” and “trait”, where the depressive episode is 
considered “state” and susceptibility to depression “trait”
5
. A pre-post design also makes it 
possible to study treatments with known clinical efficacy where the direct or downstream 
mechanism of action is unknown.  
The general aim of this thesis was to validate and apply PET methodology to study the 
serotonin and dopamine systems, their role in the pathophysiology of depression, and in the 
effects of established treatments of the disorder. 
1.2 MAJOR DEPRESSIVE DISORDER  
Major depressive disorder (MDD) is a common and devastating brain disorder, often chronic 
or recurring and with deleterious consequences in social and professional functioning as well 
as in overall health for afflicted individuals. MDD has a lifetime prevalence of about 20% 
and is twice as prevalent in women as in men
6
. It is the leading cause of disability in the 
world
7
, a fact that is explained by both the number of years lived with disease and years of 
life lost, where the latter to a substantial degree is driven by suicide. Around one million 
 
2 
individuals commit suicide every year globally; of these more than half is estimated to meet 




There exist two commonly used classification systems used for psychiatric diagnosis: the 
International Classification of Diseases, maintained by the World Health Organization, and 
the Diagnostic and Statistical Manual of Mental Disorders (DSM), maintained by the 
American Psychiatric Association. Although not identical, application of these two systems is 
considered to identify approximately the same cohort of subjects. In all studies contained in 
this thesis, the DSM criteria were applied.  
Central to the MDD diagnosis is a depressed mood and/or loss of pleasure in most activities. 
The severity of the disorder is determined by the number and severity of symptoms, and the 
degree of functional impairment. In the current version of the DSM (DSM-5
5
), five or more 
of the symptoms presented in Box 1 must be present during the same 2-week period to make 
the diagnosis of an episode of MDD. At least one of the symptoms must be either (1) 
depressed mood or (2) loss of interest or pleasure. Additionally, the symptoms must “cause 




In the studies included in this thesis, the previous version of DSM (DSM-IV 
9
) was used. The 
one significant change between DSM-IV and DSM-5 was the removal of the bereavement 
exclusion criterion, stating that the diagnosis should not be used within two months of the 
death of a loved one. 
Box 1. DSM-5 criteria for Major depressive episode 
1. Depressed mood most of the day, nearly every day. 
2. Markedly diminished interest or pleasure in all, or almost all, 
activities most of the day, nearly every day. 
3. Significant weight loss when not dieting or weight gain, or 
decrease or increase in appetite nearly every day. 
4. Insomnia or hyperomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day 
(observable by others, not merely subjective feelings of 
restlessness or being slowed down). 
6. Fatigue or loss of energy nearly every day. 
7. Feelings of worthlessness or excessive or inappropriate guilt 
nearly every day. 
8. Diminished ability to think or concentrate, or indecisiveness, 
nearly every day. 
9. Recurrent thoughts of death, recurrent suicidal ideation without 






The biological underpinnings of MDD are to a large degree still unknown. Several mutually 
non-exclusive theories exist (see Ferrari 2017 for a review
10
). Briefly, non-exhaustively, and 
in no specific order: 
1.2.2.1 Neuroplasticity 
MDD patients show smaller volumes in many brain regions, including hippocampus, when 
compared with healthy controls, and an increase in hippocampal volume has been observed in 
MDD following treatment with antidepressants 
11
. One PET study shows lower synaptic 
density in MDD patients with more severe symptoms 
12
.  
1.2.2.2 Immune system abnormalities 
The sickness behavior accompanying an infection (e.g., influenza) share many similarities 
with depression (e.g., low mood, lethargy, sleep disturbances, anxiety, loss of appetite) 
lending support to the role of the immune system in MDD
13
. Plasma levels of 
proinflammatory cytokines have been shown to be increased in patients with MDD
14
. Recent 
PET-data have shown support of cerebral immune activation in MDD
15
. 
1.2.2.3 The stress system 
Environmental stress is a well described risk factor of depression
16
. The hypothalamic–
pituitary–adrenal (HPA) system is a main regulator of stress response
16
. Dysregulation of the 
HPA system has been shown to be associated with MDD
16,17
 and treatment with 
antidepressants has been shown to normalize an impairment in the glucocorticoid-mediated 
negative feedback of the HPA system associated with depression
18
. 
1.2.2.4 The monoamine hypothesis 
In the 1960s, the discovery that drugs increasing monoamine levels in the brain were 
effective in treating depression led to the theory that depression was caused by low levels of 
monoamines
19
. Several subsequent empirical findings support the notion that monoamine 
neurotransmission is involved in MDD pathophysiology
20–22
. However, the view that low 





1.2.3.1 Cognitive behavioral therapy (CBT) 
During the 1980s and 1990s, cognitive and behavioral psychotherapeutic techniques were 
merged under the umbrella of cognitive behavioral therapy. This new approach quickly 
gained popularity and was shown to be effective in the treatment of most psychiatric 
disorders
23
. A defining feature of CBT is the idea that symptoms and dysfunctional behaviors 
often are cognitively mediated and, following from this, that various psychiatric conditions 





Specifically in the treatment of MDD, several CBT techniques have proven effective, e.g., 
behavioral activation and cognitive restructuring. An integral part of the treatment is the use 
of homework and a lot of the progress takes place between therapy sessions. CBT targeting 
MDD has comparable effectiveness as pharmacological treatment
25
.  
1.2.3.2 Electroconvulsive therapy (ECT) 
ECT has been used since the 1940s to treat both unipolar and bipolar depression. With 
remission rates above 50%
26
, it is the most effective treatment of MDD known today
27
. Using 
electricity, a seizure is induced in the brain of the patient. The procedure is performed under 
muscle relaxation and general anesthesia. Typically, 2-3 treatments are administered per 
week and usually a treatment cycle consists of 6-12 treatments.
28
 Due to the small, but non-




The molecular mechanism of action of ECT is still largely unknown. Modulation of the 





The first line pharmacological treatment of MDD are selective serotonin reuptake inhibitors 
(SSRIs)
31
 which act through blocking the serotonin transporter (5-HTT)
32
, increasing 
synaptic serotonin levels. Though there exist pharmacologic treatment options without any 
known serotonergic effect (e.g., bupropion), most common drugs targeting MDD have some 
effect on the serotonin system. It is not known how SSRIs alleviate depressive symptoms 
downstream the inhibition of the 5-HTT and though about 2/3 of patients with MDD respond 
to treatment only about 1/3 reach remission when treated with an SSRI
4
. In the studies 
included in this thesis, no pharmacological treatment was used. 
1.2.4 Criticism of the diagnosis, implications for PET research 
The MDD diagnosis has received criticism for being too heterogeneous; e.g., there are in 
theory 16,400 combinations of the criteria outlined in Box 1 that will allow a MDD diagnose 
to be made
33
. This has also been shown empirically; in one analysis over 1,000 unique 
depression-symptom profiles was observed in 3,700 patients diagnosed with MDD
33
. Further, 
the criteria for MDD do not include information regarding the length of the current episode or 
the psychosocial situation of the patient. DSM-5 has the diagnosis of “adjustment disorder” 
for excessive psychological symptoms in response to a stressor, and “persistent depressive 
disorder” for depressions lasting more than two years. However, an individual under a large 
degree of environmental stressors and with more than one year of continuous depressive 
symptoms could qualify for a MDD diagnosis as could an individual under no stress and with 
a sudden onset of symptoms two weeks prior to the diagnosis.  
Following from this it can seem unrealistic to believe that anything meaningful can be 
detected in studies with about 20 participants, a typical sample size for a clinical PET study. 
 
 5 
A counterargument to this is that even if both the cause and the symptoms of the disorder 
differ between individuals, it could well be that there exists a common biological 
underpinning somewhere in the causal path for a large majority of patients with MDD. 
In the two clinical studies in this thesis, we have tried to mitigate the problem with 
heterogeneity; in study II by including only severely ill patients requiring hospitalization, and 
in study III by only including patients with recurrent disease, i.e., with at least one prior 
episode of MDD. 
1.3 POSITRON EMISSION TOMOGRAPHY 
In contrast to X-ray radiography, where electromagnetic radiation is produced and projected 
from the scanner and detected on the other side of the body, PET functions through injecting 
a radiolabeled medical compound (radioligand), usually a drug that binds to a specific 
protein. The scanner then passively detects the radiation emitted from the body. Clinically 
PET, and its close cousin, single photon emission tomography, is mainly used to locate 
increased metabolism (e.g., malignancies, inflammatory disease)
34
, but more recently also in 
the diagnosis of Parkinson’s disease and Lewy body dementia
35
. In brain research, PET is 
among other things used to study the molecular underpinnings of neurological and psychiatric 
diseases and in the development of new drugs
36
. 
Hitherto, radioligands have been developed targeting around 50 different proteins with 
varying function (e.g., transporters, enzymes, receptors) in the human brain
37
. In theory, a 
radioligand could be developed to study almost any biological process in the body. The next 
radioligand could putatively hold the key to unlock schizophrenia, or migraine, or any other 
disorder. This virtually endless well of possible discoveries stands in sharp and important 
contrast to most other brain imaging modalities.   
1.3.1 The PET examination 
In a typical PET experiment, the radioligand is intravenously injected in tracer dose (i.e., a 
very low dose, to avoid significant occupancy and pharmacological effects
38
) into the 
research subject. After passage over the blood brain barrier, the radioligand binds to its target 
molecule. The two most used isotopes in PET radioligands are Flour-18 (
18
F) and Carbon-11 
(
11
C), both with short half-lives (about 110 min and 20 min, respectively). When the isotope 
decays, it emits a positron that travels a short distance (typically <1mm) before it meets its 
antiparticle, an electron, causing the annihilation of both the electron and the positron and 
producing two high energy (511 keV) gamma photons moving in approximately opposite 
directions.  
In the PET scanner, scintillation crystals detect gamma photons. Several rings of detector 
units surround the head of the participant. When two crystals simultaneously (i.e., within a 
few nanoseconds) detects a photon it is called a coincidence. When this happens, the system 
records a line of response (figure 1). A coincidence can either be caused by a “true”, 
“random” or “scatter” event. A random event is when, by chance, one photon from each of 
 
6 
two different decaying positrons hit detectors simultaneously; scatter is when a photon 
changes direction on the way to the detector ring due to interaction with other particles. Both 
random and scatter events add noise to the data; this is addressed through automated 




Figure 1.  The positron meets an electron and is annihilated, resulting in two gamma photons 
traveling in opposite direction. The photons interact with scintillation crystals in the detector 
ring causing a coincidence and the PET-system registers a line of response (the red line 
passing through the head in the image). The stored data is reconstructed to a 3D image. 
Modified image from the public domain (created by Jens Maus). 
1.3.2 Quantification of PET-data 
When nuclear imaging is used in the clinic (e.g., to look for cancer metastasis), quantification 
of the radioligand binding is not always necessary. In brain research, however, commonly 
groups of individuals are to be compared, making binding quantification a necessity.  
The information contained in PET data for a given examination in a given brain region is the 
total radioactivity concentration (denoted CT, commonly expressed as kBq/mL) over time. 
This value will vary depending on several factors aside from the density of the protein that is 
to be quantified (e.g., injected dose, body mass, rate of radioligand metabolism, etc). To be 
able to make comparisons between examinations effectively, the data therefore needs to be 
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normalized. An easy, albeit error-prone, way to do this is through calculating a Standardized 
Uptake Value (SUV) where CT is divided by injected dose and body mass. A more reliable 
method is to calculate the ratio of CT to some reference concentration. If arterial blood is 
collected during the examination, the volume of distribution (VT) can be calculated. 
Conceptually, VT can be thought of as the amount of plasma units needed (at equilibrium) to 
reach the same radioactivity as one unit of tissue. For example, a VT of 5 in a brain region of 
1 cm
3
 means that a volume of 5 cm
3
 plasma would be needed to reach the same amount of 
radioactivity as what was recorded in the brain tissue
39
. 
Quantification methods using arterial blood as an input function require relatively few 
assumptions and are commonly considered gold standard in PET quantification; however the 
process of gathering this data is cumbersome, uncomfortable for the research subject, and 
adds to the sources of potential measurement error. It is therefore common to apply reference 
tissue quantification whenever possible. A valid reference region should be devoid of the 
protein that is quantified (i.e., no specific binding of the radioligand) and the non-specific 
uptake should be the equal to the target region. The typical outcome measure when applying 
reference tissue quantification is BPND, the binding potential with respect to non-displaceable 
uptake. BPND is the ratio of the concentration of specifically bound (CS) to non-displaceable 
radioligand (CND) at equilibrium:  
     
  
   
                                                                                                                               (1) 
CND is defined as the combined uptake from free and non-specifically bound radioligand. The 
term non-displaceable is derived from the fact that, in contrast to specifically bound 
radioligand, free and non-specifically bound radioligand is not “displaced” by a drug that 
competes at the binding site. Just based on the PET measurement from the target region (i.e., 
CT), there is no reliable way to disentangle what part of the registered radioactivity is due to 
CND and what is due to CS. However, using a reference region as a surrogate for the CND, 
BPND can be calculated according to (at equilibrium): 
     
  
      
   
         
  
                           (2) 
BPND calculated using reference tissue methods can thus be described as “how many percent 
more radioactivity is measured in the target region compared to the reference region”. A 
reference tissue generated BPND of 0.5 means that there is 50% more radioligand present in 
the target region compared with the reference region, and, if all assumptions hold, that there 
is twice as much non-displaceable as specifically bound radioligand in the target region. 
BPND is unitless and the value holds no interesting biological information in itself, but derives 






1.3.3 A short note on consequences of violations of the assumptions of 
reference tissue methods 
To appreciate the results of study I, it is helpful to understand two points on how the BPND 
estimate is affected when assumptions underlying reference tissue quantification are violated: 
(1) If the reference tissue uptake is lower than the true non-displaceable uptake in the target 
region, then the BPND estimate will be biased upwards, while the opposite effect (false low 
BPND) will be the result if the reference uptake is higher than the true non-displaceable 
uptake. (2) If the ratio of specific binding to non-displaceable uptake is low in the target 
region (i.e., a low “true” BPND), then small violations of the reference tissue assumptions will 
have a big effect on the BPND estimate (Box 2 for an example). Consequently, it becomes 
even more important to check the validity of the BPND estimates in low binding regions 
before interpreting results from these regions. See Salinas
40
, for an in-depth discussion of 
violations of reference tissue models. 
 
    
     
  
      
   
       
   
 
     
    
         
  
      
   
   
  
   
 
       
   
      
    
     
  
      
   
       
 
 
   
    
         
  
      
   
   
  
   
 
     
   
     
Box 2. To illustrate the difference in consequences of violation of 
reference tissue assumptions between low and high binding regions, 
consider 10% lower tissue radioactivity concentration in the 
reference region (  
   
=0.9) compared with non-displaceable uptake 
in the target region (   
      
=1), in two cases: 1) specific binding 
(  
      
),  is 0.1, and 2) where   
      
 is 5.  
Case1:  
Case 2:  
In case 1, the observed BPND is 120% higher than the true value, 
while, in case 2, the observed BPND is 14% higher. The same 
absolute difference in non-displaceable uptake between target and 




1.3.4 Validity and reliability of radioligand binding estimates 
As part of the development of a new radioligand validity and reliability of the binding 
quantification must be assessed. A visual representation of the classical interpretation of 
validity and reliability can be seen in figure 2. In short, a measuring method is valid if it 
measures what it purports to measure (i.e., it has a low degree of bias)
41
; it is reliable if a 
result can be reproduced when the measurement is repeated under the same conditions.
42
   
In the field of PET, validity is usually defined as whether, and to what extent, a radioligand 
binds to the protein of interest. A common approach to test the validity of a radioligand is 
through a pharmacological challenge, in which PET experiments are performed before and 
after pretreatment with a competitor, i.e., a drug binding to the same target as the radioligand, 
but from a different chemical class. Reduced binding after pretreatment is a sign of validity. 
Reliability is usually interpreted as repeatability, i.e. to what degree do we achieve similar 
results when the same phenomenon is measured more than once. In this context, the center of 
the arrowboards in figure 2 can be viewed as the true underlying quantity and the blue crosses 
as repeated measures. This is commonly evaluated using a test-retest design in which a group 
of individuals are examined twice with the same radioligand. The variability of the 




Figure 2. A measure can deviate from the “true” score in two ways. Either through a 
systematic deviation (i.e., bias) from the true score (left panels vs. right panels), or through a 
high degree of variance (upper panels vs. lower panels).  
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1.4 BRAIN NEUROTRANSMISSION 
The cells that make up the human brain can be sorted in two categories: glial cells and 
neurons
43
. Glial cells produce no electrical impulses, and their main function is to support the 
neurons
44
. Neurons are structurally and functionally diverse and complex cells that transmit 
electrical signals (action potentials) and communicate with other cells through converting the 
action potential to a chemical signal
45
. The point of communication is called a synapse, and 
there are many synapses in the brain. It has been estimated that the about16 billion neurons
43
 
in the human cerebral cortex each has 7000 synapses
46
, totaling 0.15 quadrillion synapses, or 
10
12




. In the synapse, the presynaptic neuron 
releases a molecule (neurotransmitter) that interacts with receptors on the postsynaptic neuron 
(figure 3)
48
. The chemical transmission can also occur through volume transmission, where 






Figure 3. Schematic image of a synapse. Neurotransmitter is released to the synaptic cleft 
from synaptic vesicles in the presynaptic neuron. The neurotransmitter interacts with 
receptors, either on the postsynaptic neuron (heteroreceptors) or on the presynaptic neuron 
(autoreceptors). The signal is terminated through transport back into the presynaptic neuron 
via a reuptake transporter. Source: Modified image purchased at istockphoto.com 
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Two broad families of receptors are present in the central nervous system: metabotropic and 
ionotropic receptors
45,50
. Upon activation by a neurotransmitter, a ionotropic receptor opens a 
linked ion channel allowing the influx of ions to the cell, whereas a metabotropic receptor 
triggers a second messenger system (e.g., through activating a G-protein) within the neuron
45
. 
Neurons are commonly classified according to the (main) neurotransmitter they produces. 
The vast majority of neurons in the brain produce either gamma-Aminobutyric acid (GABA) 
or glutamate
48
. The effect of GABA neurotransmission is usually inhibitory (decreasing the 
chance of an action potential occurring) and for glutamate excitatory (increasing the chance 
of an action potential occurring). However, the effect of any neurotransmitter depends on the 
type of receptors on the post-synaptic neuron.  
1.4.1 Monoamine neurotransmitters 
The monoamines constitute a functionally important group of neurotransmitters. With regard 
to psychiatric and neurological disorders, the three monoamines dopamine, serotonin and 
norepinephrine are most relevant
48
. In this thesis, the serotonin and dopamine systems are 
studied.  
Following synthesis (for dopamine from the amino acid tyrosine and serotonin from 
tryptophan), the neurotransmitters are loaded into synaptic vesicles through the vesicular 
monoamine transporter 2. After depolarization of the presynaptic neuron, the vesicle is 
released to the synapse
48
. For both dopamine and serotonin, a large part of the chemical 
transmission has been suggested to occur through volume transmission
49
. The primary 
mechanism of termination of the signal is through active transport back into the presynaptic 
neuron; for dopamine through the dopamine transporter, and for serotonin through the 5-
HTT. Both neurotransmitters are catabolized to inactive metabolites by enzymes, monoamine 
oxidase A and B, and for dopamine also by catechol-O-methyltransferase
48
.   
1.4.2 Dopamine 
The dopamine system in man consists of around 400.000 neurons with the cell bodies mainly 
situated in substantia nigra and the ventral tegmental area in the midbrain, with projections to 
cortex, limbic structures and basal ganglia.
51
 The relatively small number of dopamine 
neurons (less than 0.005 ‰ of the total amount of neurons
43
)  does not stand in relation to 
their functional importance. Dopaminergic neurotransmission is, among other things, central 
to functions like movement and reward
52,53
 and is implicated in the pathophysiology of both 
neurological ( e.g., Parkinson´s disease
54
) and psychiatric disorders (e.g., mood disorders, 
schizophrenia
55
 and substance abuse
56
). 
1.4.2.1 Dopamine receptors 
There are five subtypes of dopamine receptors described, all metabotropic and G-protein 
coupled
48
. They are typically divided into two groups, dopamine 1-like receptors and 
dopamine 2-like receptors (D2R)
57
. Of the two, D2R is the variant most implicated in the 





1.4.2.2 Dopamine and depression 
Postmortem studies of patients who suffered from depression have shown reduced levels of 
dopamine metabolites in cerebrospinal fluid (CSF) and in brain striatal brain regions 
compared with healthy controls.
58
 Postmortem receptor data are more contradictory with 
some studies showing higher density of dopamine receptors in striatum and amygdala
59–61
. 





, or no significant difference, compared with 
controls
64
. A possible limitation of these studies is that only out-patients were included, a 
group that usually displays less severe symptoms compared to hospitalized patients. 
Psychomotor retardation and parkinsonism – symptoms well known to be associated with 




Serotonin is a neurotransmitter found in most living things, including plants and algae
66,67
. In 
man, it is most abundantly found in the gut where it regulates digestion
68
. Similar to the 
dopamine system, the amount of serotonin neurons located in the central nervous system is 
vanishingly small relative to the total number of neurons
67
, but, as is the case with dopamine, 
this does not mirror their functional importance. Serotonergic neurotransmission has been 
shown to affect body temperature, mood, sleep, eating behavior, sexual behavior, cognition 
and pain
67,68
, and has been implicated in a large number of brain disorders, e.g., migraine, 
depression, schizophrenia and autism
67
. The cell bodies of serotonin neurons are mainly 
located in the raphe nuclei in the brainstem from where they project to a broad array of 
cortical and subcortical regions
67
. 
1.4.3.1 Serotonin receptors and transporter 
Presently, 14 variants of serotonergic receptors are described; they are classified into seven 
families (5-HT1–7) based on their molecular and biological characteristics
67,69
. Except for the 
ionotropic 5-HT3 receptor, all serotonin receptors are metabotropic and G-protein coupled
70
. 
The receptors that have most often been implicated in psychiatric disorders are the inhibitory 
serotonin 1A and 1B and excitatory 2A receptors (5-HT1A; 5-HT1B and 5-HT2A)
45,71,72
. 5-
HT1A and B function both as heteroreceptors and as autoreceptors regulating 
neurotransmission
48,73
 (figure 3). Upon binding to a 5-HT1A or B autoreceptor, serotonin 
inhibits formation of the second messenger cyclic adenosine, thereby decreasing release of 
serotonin to the synapse
71
. The serotonin transporter, 5-HTT, is the main route of clearing 
serotonin from the synapse
48




1.4.3.2 Serotonin and depression 
A number of findings support the role of serotonin in MDD: serotonin metabolite levels in 
CSF of MDD patients has been shown to be decreased compared to controls
20
; further, 
depletion of tryptophan, the precursor to serotonin, has been shown to induce lower mood in 
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MDD patients in remission
74
; and, importantly, the symptoms of depression are alleviated 
when patients suffering from MDD are treated with pharmacological agents known to 
increase cerebral serotonin levels
4,19
. In the study of depression using in vivo PET, 5-HTT it 
the protein that has been most extensively researched. Though individual results differ, meta-
analyses indicate reduced 5-HTT availability in patients with MDD
75,76
.  For 5-HT1B only 
two small (both n=10) patient-control PET studies have been published, both showing low 5-








In this thesis, PET methods were validated (study I) and applied to study aspects of the 
serotonin and dopamine systems in major depressive disorder. This was done through patient 
and control comparisons (study II and III), by examining correlations between key serotonin 
proteins (study IV), and through a longitudinal approach testing patients before and after 
treatments with known efficacy (study II and III). 
The specific aims were as follows: 
In study I, the validity and reliability of quantification of the radioligand [
11
C]raclopride 
outside of striatum was evaluated. 
In study II, dopamine D2 receptor density was compared between healthy controls and 
patients with severe depression, and patients before and after electroconvulsive treatment. 
In study III, brain serotonin transporter density was compared in healthy controls and patients 
with depression, and in patients before and after cognitive behavioral therapy. 
In study IV, the correlation between serotonin transporter availability and serotonin 1B 




3 MATERIAL AND METHODS 
 
All studies were approved by the Ethics Committee of the Stockholm Region, and the 
Radiation Safety Committee of the Karolinska University Hospital. All subjects gave their 
written and verbal informed consent before initiation of study procedures.  
3.1 STUDY SUBJECTS 
All subjects were healthy according to: clinical interview, magnetic resonance (MR) imaging 
of the brain, physical examination, routine blood tests, and urine drug screen both at inclusion 
and at the day of PET examinations. Aside from a diagnosis of MDD for patients in study II 
and III, the subjects had no history of diseases involving the central nervous system, or any 
history of alcohol use disorder or drug addiction. 
Subjects in study I consisted of two cohorts, the healthy controls from study II (see below), 
and eleven healthy male subjects (25±2.5 years, mean±SD) that participated in a previously 
published study
79
. Patients in study II (n=9; 3 males; 48±11 years) were recruited at 
psychiatric wards in Stockholm, Sweden. The controls (n=9; 3 males; 51±12 years), matched 
for age and sex, were recruited via advertisement in local newspapers. In study III, patients 
(n=17; 4 males; 47±13 years) and healthy control subjects (n=17; 4 males; 47±14 years), 
matched for age, sex and intellectual ability were recruited by advertisements in local 
newspapers. The healthy controls from study III also participated in study IV.  
3.2 STUDY INTERVENTIONS 
3.2.1 Quetiapine 
Quetiapine is a multimodal drug with D2R antagonist properties
80
. The drug is used in 
psychiatric care to treat various conditions, including psychotic disorders, bipolar disorder 
and as an adjunctive treatment to MDD
81
. In study I, PET-data from a previously published 
occupancy study of quetiapine was reanalyzed to evaluate D2R competition of [
11
C]raclopride 
binding in extrastriatal brain regions.  
3.2.2 ECT 
In study II, hospitalized patients with severe depression were treated with ECT. See section 
1.2.3.2 for an overview of ECT.  
3.2.3 Internet-delivered cognitive behavioral therapy (ICBT) 
In study III, patients with MDD were treated with ICBT. The main component of the ICBT 
treatment program is 10 text modules covering specific themes such as psychoeducation and 
behavioral activation. The modules end with a home assignment. All participants are assigned 
an online psychologist with thorough training in CBT. The psychologist supervised the 
progress and provided individual feedback on home assignments. The standard duration of 
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treatment is 12 weeks. ICBT has been found to be as effective as face-to-face CBT, and is 
now a standard treatment option
82
. The ICBT treatment protocol applied in study III has been 
tested in randomized trials
83
, and has been shown to be effective in clinical practice 
84
. 
3.3 PET EXAMINATIONS 
The PET examinations in all studies were performed using a High Resolution Research 
Tomograph (HRRT; Siemens Molecular Imaging, USA) with a maximum spatial resolution 
of about 2mm full-width-half-maximum
85
. 
Before the PET examination, a plaster helmet was made for each subject and used with a 
head fixation device in order to minimize head movement in the scanner 
86
. Transmission 
scans were performed prior to each PET examination in order to correct for signal 
attenuation. In each PET experiment, a saline solution containing the radioligand was injected 
into an antecubital vein as a bolus (<10 seconds). The cannula was thereafter immediately 
flushed with 10 mL saline. Brain radioactivity was recorded continuously for 51–93 minutes 
depending on the radioligand applied. The resulting data was reconstructed in 3D and binned 
into consecutive time frames.  
3.3.1 Applied Radioligands 
3.3.1.1 [11C]raclopride 
The dopamine D2R binding radioligand [
11
C]raclopride was developed in the 1980s
87
 and is 
one of the most frequently used PET radioligands in brain research to date. Due to its 
relatively low affinity for D2R (Kd = 1.3 nM), [
11
C]raclopride has primarily been used to 
study receptor availability in striatal regions. The validity and reliability for quantification of 
[
11
C]raclopride binding in striatum is well established
88–90
. Extrastriatally, however, where 
the concentration of D2R ranges from 1–10% of that in striatum
91
, the data is sparse. 
[
11
C]raclopride was used in study I and II and was prepared as described previously
92
. 
3.3.1.2  [11C]MADAM 
[
11
C]MADAM was developed at Karolinska Institutet’s PET group in the early 2000s. It is a 
radiolabeled selective 5-HTT inhibitor, N,N-dimethyl-2-(2-amino-4-





C]MADAM is similar both in chemistry and pharmacokinetic properties to [
11
C]DASB, a 
more widely used 5-HTT radioligand. [
11
C]MADAM was prepared by methylation, using 
[
11
C]methyl triflate, as previously described
93
, and used for quantification of 5-HTT in 
studies III and IV. 
3.3.1.3 [11C]AZ10419369 
The 5-HT1B receptor radioligand [
11
C]AZ10419369 was developed as a joint venture 












C]AZ10419369 was prepared by methylation, using [
11
C]methyl triflate, as previously 
described
97
 and was used for quantification of 5-HT1B receptors in study IV. 
3.3.2 Image processing 
T1-weighted MR images were acquired using a 1.5 Tesla (part of studies I and II), or a 3 
Tesla (studies III and IV and part of studies I and II) GE Signa system (GE Medical Systems, 
USA).  
3.3.2.1 Image preprocessing 
The dynamic PET images were corrected for head motion using a between-frame-correction 
algorithm implemented in Statistical Parametric Mapping (SPM, Wellcome Department of 
Cognitive Neurology, University College, London, UK). Using SPM the T1-weighted MR 
images were then co-registered to a summated PET image. To derive regional time-activity 
curves (TACs), the resulting co-registration matrix was used to project regions of interest 
(ROIs) on the realigned dynamic PET-image. 
3.3.2.2 Regions of interest 
For all studies, FreeSurfer (version 6.0, http://surfer.nmr.mgh.harvard.edu/)
98
 was applied to 
the MR images to generate the reference tissue ROI. In studies I, III and IV, the FreeSurfer 
segmentation was also used to define the ROIs included in the analysis.  
In study II, ROIs were defined using an atlas of functional, connectivity-based, subdivision of 
striatum
99
. The atlas was projected to the dynamic PET data in two steps: first via 
transformation to each subject’s MR image using the FLIRT and FNIRT functions in FSL5 
(FMRIB Software Library v5.0), and then via co-registration to the summated PET image, 
using the MR-to-PET co-registration matrix. 
3.3.2.3 Quantification 
Quantification using reference tissue methods were applied in all studies. Cerebellar gray 
matter was used as reference since negligible amounts of specific binding have been observed 
here for all three radioligands
91,97,100,101
. In all studies, BPND was used as the parameter of 
interest. 
In studies I and II, the simplified reference tissue model (SRTM)
102
 was applied. SRTM was 
originally developed to improve reference tissue quantification of [
11
C]raclopride binding and 
has been shown to often produce good fits with stable parameter estimation of kinetic PET 
data
103
. In addition to the assumptions underlying all reference tissue models (see 
section1.3.2), the SRTM assumes that radioligand kinetics can be represented by a one-tissue 
model in both reference and target tissue
40
. 
The Logan graphical analysis is a linear method for quantification of PET data
104
 requiring no 
assumptions of compartment kinetics. In studies III and IV, a multilinear version of the non-
invasive Logan model was used to calculate BPND
105
. The model requires the time at which 
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the linear phase starts (t*) as input. For [
11
C]MADAM, t* was set to 45 minutes, 
corresponding to 8 frames; for [
11
C]AZ10419369 t* was set to 33 minutes, corresponding to 
10 frames. The reference region efflux rate constant (k2’) is also needed as input, either in the 
form of a population average, or from each individual. In studies III and IV the k2’ was 
derived using the SRTM in representative regions for each individual. 
Parametric images were generated using the 3D stationary wavelet-aided parametric imaging 
(WAPI) procedure, where the non-invasive Logan plot, fitted with multilinear regression, is 




In study I, a paired one sided t-test was used to evaluate differences in regional BPND values 
obtained at baseline and after quetiapine administration. Absolute variability (VAR) and 
intraclass correlation coefficient (ICC) was used to evaluate test-retest reliability (see below). 
In study II, a repeated measures, between-group analysis of variance was used to test the 
difference between groups over time (i.e., if ECT treatment in patients with MDD changed 
[
11
C]raclopride binding when compared with controls measured twice). Paired two sided t-
tests were used to test for baseline differences between patients and controls. Pearson´s 
correlation coefficients were calculated to assess associations between variables. Effect sizes 
were quantified using Cohen's dz, i.e., a paired version of the classical Cohen's d where the 
standard deviation of the difference score is used as denominator
107
. 
In study III, paired t-test was used to assess differences in [
11
C]MADAM BPND within 
patients before and after CBT (two sided), as well as between patients at baseline and their 
matched control subjects (one sided). A multilevel model for repeated measures was used to 
assess change in the score of self rated Montgomery Asberg Depression Rating Scale 
(MADRS-S)
108,109
, used as a marker for depression symptom load. To test for an association 
between change in MADRS-S and [
11
C]MADAM BPND, individual slopes from the 
MADRS-S multilevel model were entered as an independent variable into a regression 
model, predicting BPND from PET2 while controlling for BPND from PET1.  





C]AZ10419369 BPND in relevant brain regions, while 
controlling for age. The reason for controlling for age is that the expression of both 5-HTT 
and 5-HT1B have been shown to decrease with age
110,111
. 
All statistical analyses and data visualization were performed using R
112
. 
3.4.1 Multiple comparisons 
In study I and IV, no corrections for multiple comparisons were performed due to an 
exploratory analytical approach in these studies. In study II, Bonferroni correction was 
applied. In study III, the analysis protocol (both image and statistical analysis) was 
preregistered and the analyses were clearly marked as “confirmatory” or “exploratory”. Two 
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confirmatory comparisons were made for each of the two research questions tested. In the 
longitudinal analysis, no correction was made since there was a strong correlation between 
the compared variables. In the cross-sectional analysis, a Bonferroni correction was applied. 
3.4.2 Test-retest metrics 
3.4.2.1 Absolute variability (VAR) 
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VAR is a measure of the absolute reliability of a measurement expressed as a percentage of 
the average BPND value. PET1 refers to the first PET measurement, and PET2 refers to the 
second PET measurement. The reported value is the average VAR for all subjects. 
 
3.4.2.2 Intraclass correlation coefficient (ICC) 
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where MSB denote the between-subjects mean sum of squared variance and MSW the within-
subject mean sum of squared variance. ICC normalizes the measurement error to the 
between-subject variance and will give information on how well a test can distinguish 
between individuals. The score can vary between 1 and -1, values closer to 1 indicate that 







4 RESULTS AND COMMENTS 
 
4.1 STUDY I: VALIDITY AND RELIABILITY OF EXTRASTRIATAL 
[11C]RACLOPRIDE BINDING QUANTIFICATION IN THE LIVING HUMAN 
BRAIN 
Very little is published on the validity of [
11
C]raclopride binding quantification outside of the 
striatum. Despite this, binding data for regions with low density of D2R, e.g., the neocortex, is 
frequently reported in the scientific literature. The primary aim of study I was to assess the 
validity and reliability of extrastriatal [
11
C]raclopride binding quantification. Validity was 
assessed through reanalyzing an occupancy dataset where eleven healthy subjects were 
examined with [
11
C]raclopride PET before and after dosing with an extended (XR) and 
immediate release (IR) formulation of 300 mg quetiapine, a D2R antagonist. Reliability was 
assessed using a test-retest design where a separate sample of nine healthy controls were 
examined twice with [
11
C]raclopride PET. 
Significant decrease in [
11
C]raclopride BPND following pretreatment with quetiapine was 
observed in all striatal regions, the temporal cortex (TC) and the thalamus, but not in frontal 
regions (Figure 4 and 5). 
 
Figure 4. MRI and parametric PET images for one subject. A) MRI with regions of interest 
overlaid B) [
11
C]raclopride binding at baseline C) [
11
C]raclopride binding after 
pretreatment with quetiapine. DLPFC, dorsolateral prefrontal cortex. 
In putamen, the percentage decrease (i.e., the occupancy value for quetiapine) of 
[
11
C]raclopride BPND in the IR examination was 50.6±4.1% (mean±SD), in thalamus 
19.5±16.6% and in TC 17.8±16.8%. The occupancy in TC and thalamus was significantly 
lower compared to the occupancy in putamen. The analysis of the test-retest data using 
equation 3 for calculation of VAR and 4 for calculation of ICC showed a VAR of 3.7% and 
ICC 0.88 in putamen; in thalamus 16.6% and 0.27, (VAR and ICC respectively); in TC 
13.8% and 0.7; in dorsolateral prefrontal cortex 26% and 0.81. 
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Figure 5. BPND data. For each ROI three PET examinations were analyzed. From left to 
right: Baseline (red); after Quetiapine XR pretreatment (green); after Quetiapine IR 
pretreatment (blue). Horizontal bars represent mean BPND. Each shape represents one 
subject. DLPFC, dorsolateral prefrontal cortex; ACC, Anterior cingulate cortex; TC, 
Temporal cortex 
The observation of lower occupancy in thalamus and TC compared with striatum, and no 
significant decrease of [
11
C]raclopride binding in frontal regions, indicates that some degree 
of the BPND estimates in these regions reflect something else than specific binding. Using the 
arrowboard analogy presented in figure 2, the lower right panel (high bias and high variance) 
best describes the results we observe in most extrastriatal regions.  
4.2 STUDY II: [11C]RACLOPRIDE POSITRON EMISSION TOMOGRAPHY 
STUDY OF DOPAMINE-D2/3 RECEPTOR BINDING IN PATIENTS WITH 
SEVERE MAJOR DEPRESSIVE EPISODES BEFORE AND AFTER 
ELECTROCONVULSIVE THERAPY AND COMPARED TO CONTROL 
SUBJECTS 
In study II, [
11
C]raclopride PET was used to study D2R in severely depressed patients before 
and after ECT and in a matched cohort of healthy controls measured twice and receiving no 
intervention. The main hypothesis tested in this study was that D2R binding would be 
different in MDD patients compared to controls. The secondary hypothesis was that ECT 
would be associated with a change in D2R binding towards that of the control group. 
For two patients, the post-treatment PET examination had to be excluded from analysis for 
technical reasons. The patient-control comparison was thus performed in nine patients and 
nine controls, while the longitudinal analysis (before and after treatment) was performed in 
seven patients and seven matched controls. MDD symptoms were quantified at the time of 
PET using MADRS. 
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MADRS at baseline was 35±7 and after treatment 12±4 (p<0.001). The analysis of the 
baseline [
11
C]raclopride BPND between patients and controls showed a significantly lower 
D2R availability in patients in all three examined regions (p<0.05 corrected for multiple 
comparisons) (figure 6, panel A). The average [
11
C]raclopride BPND increased 10–17% in the 
three regions after ECT, corresponding to Cohens dz of 0.37–0.65; however the repeated 
measures between-group analysis comparing the pre and post PET measurements of patients 




C]raclopride binding potential (BPND) in the executive, limbic, and sensorimotor 
striatum in (A) patients with major depressive disorder (MDD) pre electroconvulsive therapy 
(ECT; red) and control subjects (blue; n = 9) and (B) MDD patients pre- (red) and post-ECT 
(gray; n = 7; subject identity is indicated by the shape of the marker). Horizontal line 




The results support the notion that severe MDD is associated with lower D2R binding in 
striatum. We noted a non-significant, numerical increase in D2R binding in the patient group 
after response ECT. 
4.3 STUDY III: SEROTONIN TRANSPORTER AVAILABILITY INCREASES IN 
PATIENTS RECOVERING FROM A DEPRESSIVE EPISODE 
The primary aim of study III was to compare serotonin transporter availability between 
healthy controls and patients with depression, as well as between pateitents before and after 
psychotherapy. The longitudinal design, in combination with a treatment that has no known 
direct effect on the serotonin system, makes it possible to study 5-HTT during the natural 
course of a depressive episode. Previous molecular imaging studies have shown low cerebral 
concentration of 5-HTT in MDD patients
75
. Whether or not this also is present before disease 
onset and after remission (i.e. a trait), or only at the time of the depressive episode (i.e. a 
state) is a research question possible to address with this design. 
Seventeen patients with an episode of MDD were examined twice with [
11
C]MADAM PET, 
before and after treatment with ICBT. 17 matched healthy control subjects were examined 
once with [
11
C]MADAM PET. Confirmatory analysis of the longitudinal and cross-sectional 
data were performed in 1) a composite region consisting of eight pre-specified cerebral 
regions and 2) in the median raphe nuclei. The treatment effect was evaluated using 
MADRS-S. 
The MADRS-S score at start of the CBT treatment was 28±4 and at completion of treatment 
15±9, the decrease was significant (p<0.001). In the longitudinal PET analysis, 
[
11
C]MADAM binding increased on average by 10% in the composite region following CBT 
(p = 0.01). No change was observed in the median raphe. In the cross-sectional (patient-
control) comparison, no evident difference in [
11
C]MADAM binding was observed in the 





Figure 7. In (A) MADRS-S measurements during the course of CBT. Each cell represents one 
patient. In (B) longitudinal [
11
C]MADAM data, PET1 (baseline) and PET2 (after treatment). 
Right panel shows difference scores between scans. In (C) mean parametric image of patients 
at baseline (upper image) and after treatment (lower image). In (D) longitudinal data, 
median raphe, BPND at PET1 (baseline, left) and PET2 (after treatment, right). In (E) cross-
sectional data, median raphe, BPND for patients with MDD at baseline (left) and healthy 
controls (right). In (F) cross-sectional [
11
C]MADAM data, comparing patients with MDD at 
baseline to matched healthy controls. Right panel shows difference scores between matched 
pairs. 
 
The fact that the control group only performed one PET examination is a limitation of the 
study design, adding to the list of assumptions needed in order to draw any causal inference 
from the results. Under the null hypothesis that 5-HTT have no association to either 
depression or CBT treatment, we would expect no change in [
11
C]MADAM binding between 
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PET1 and PET2. Lacking a second measurement in the controls, we can still make the 
(reasonable) assumption that there should be no systematical change in [
11
C]MADAM when 
a healthy control is examined twice with a few weeks apart. This would imply that the 
observed increase in cerebral [
11
C]MADAM binding as MDD patients improve in their 
symptoms is caused either as a direct effect by the CBT treatment or by the alleviation of 
depressive symptoms. 
4.4 STUDY IV: IN VIVO CORRELATION OF SEROTONIN TRANSPORTER AND 
1B RECEPTOR AVAILABILITY IN THE HUMAN BRAIN – A PET STUDY 
Both the 5-HT1B receptor and 5-HTT are important in regulating cerebral serotonergic 
transmission, and both proteins have been implicated in the pathophysiology of MDD. In 
study IV, the primary aim was to investigate whether a correlation was present between 5-
HTT and 5-HT1B expression in the brain of healthy individuals. 
Seventeen healthy individuals were examined with PET twice the same day using the 
radioligands (in a random order) [
11
C]AZ10419369, binding to 5-HT1B, and [
11
C]MADAM, 
binding to 5-HTT. BPND was calculated for a set of ROIs, including median and dorsal raphe, 
and the correlation between the binding estimates of the two radioligands was calculated 
using partial Pearson correlation coefficient, controlling for age.  




C]MADAM BPND correlation was 
positive in all examined brain regions. In most cortical regions, the correlation was strong, 
e.g., in the temporal cortex, r(15) = 0.6, p =0.01 and in the parietal cortex, r(15) = 0.79, p < 
0.01, while in most subcortical regions, the correlation estimate was very weak (figure 8). No 









C]MADAM BPND in different brain 
regions. The reported correlations are controlled for age. To visualize the effect of age 
lighter grayscale is used for younger subjects and darker for older subjects in the scatter 
plots. ACC, Anterior cingulate cortex; PCC, Posterior cingulate cortex 
 
The strong correlation observed in cortical regions must be interpreted with caution. 
[
11
C]MADAM BPND is low in most of the cerebral cortex, with specific binding several times 
lower compared with the non-displaceable uptake. This means that random variation of non-
interesting phenomena (e.g., differences in anatomy of the reference region, small 
discrepancies in the delineation ROIs) may have a substantial impact on the quantification, 
and, importantly, could affect the BPND estimate of both radioligands in the same direction. In 
support of this interpretation a high correlation (r=0.66, p=0.006) was observed in the 
centrum semiovale, a brain region only containing white matter. In brain regions with good 








Study I:  In most brain regions outside striatum, little or no decrease in BPND was observed 
after pretreatment with a competitor, lending no support for valid [
11
C]raclopride binding 
quantification here. We suggest that a violation of reference tissue assumptions (lower CND in 
the reference tissue compared with the target regions), inflating the BPND estimate in 
extrastriatal regions, is the most likely cause for our results. Extrastriatal test-retest 
repeatability was relatively poor in most regions. Our findings indicate that [
11
C]raclopride 
PET is not suitable for quantification of D2R in most regions outside of striatum. At a 
minimum, our results cannot establish satisfactory validity in extrastriatal regions, and any 
researcher who wishes to publish studies using [
11
C]raclopride data in these regions should 
perform an independent validation study. The results from study I were used when deciding 
on the analysis plan for study II.  
Beyond the implications for [
11
C]raclopride research, the results in study I raises questions 
regarding the interpretation of test-retest metrics in PET research. ICC normalizes the 
measurement error to the between-individual variance. Higher between-individual variance 
will increase the ICC (indicating better reliability), other things being equal. Our results 
indicate that extrastriatal [
11
C]raclopride BPND is biased due to a violation of reference tissue 
assumptions. If the size of the bias is not identical between individuals, the between-
individual variance will increase. Assuming the bias is stable between measurements, we 
would expect ICC to be overestimated. The VAR is sensitive to the magnitude of the signal. 
Given a (stable) bias inflation of BPND, the VAR will be underestimated (indicating better 
reliability). There is thus a risk that reliability metrics can indicate a false high reliability due 
to a lack of validity in the outcome measure. This can create a veneer of credibility for a 
measurement where little or no connection to the target it purportedly measures exists. Before 
interpreting reliability metrics of a radioligand, it is therefore important to establish validity. 
This is especially pertinent in low-binding regions where violations of assumptions in the 
quantification method will have a disproportionally large effect.  
Study II: The role of dopamine transmission in affective disorders is unclear, as is the 
molecular mechanism of action for ECT, the most effective MDD treatment known. In study 
II, we used [
11
C]raclopride PET to quantify striatal D2R binding before and after a treatment 
series of ECT in patients hospitalized due to MDD. We also examined a group of matched 
healthy controls twice. The results showed an association between severe MDD and lower 
dopamine D2R binding in striatum, compared with controls. The [
11
C]raclopride BPND 
increased (i.e., in the direction of the controls) after response to ECT. However due to the 
small sample size, we were powered to detect only large effects, and though the average 




Study III: An increase in 5-HTT availability was observed as depressive symptoms were 
alleviated in patients suffering from a MDD episode. These results suggest a degree of 
plasticity in the serotonin system with regard to depressive episodes, indicating that 
previously reported cross-sectional findings of lower 5-HTT binding in patients with MDD 
compared with controls most likely reflect the depressive state rather than a trait. 
A speculative interpretation of the results in study III is that the observed increase in 5-HTT 
binding could constitute the normalization of a system attempting to compensate for the stress 
associated with a depressed state. Under this model, environmental stress decreases cerebral 
5-HTT availability as (part of) an adaptive response. Some individuals will still develop 
MDD, after which, hypothetically, either continual environmental stress or the stress inherent 
to the depressive state will keep 5-HTT levels low. As the patient recovers, either due to 
spontaneous remission or treatment, e.g., CBT, 5-HTT levels could be expected to increase 
towards premorbid levels. 
Study IV: The analysis plan in study IV was not preregistered and the correlation between 5-
HTT and 5-HT1B BPND was tested in a large number of brain regions in an exploratory 
approach. We observed strong correlations mainly in cortical regions where 5-HTT density is 
known to be low. A similarly strong correlation was observed in centrum semiovale. The 
explanation that these results are driven by an artifact must therefore be considered and the 
results interpreted with caution. If the results are due to a true underlying correlation between 
the expression of 5-HTT and 5-HT1B in cortex, this opens up for interesting interpretations. 
The strictly pre-synaptic 5-HTT and, in cortex, mainly post-synaptic 5-HT1B are synthesized 
by different neurons. A strong correlation between the expression of the two proteins could 







6 ETHICAL CONSIDERATIONS 
 
From an ethical perspective, the characteristic that sharply distinguish PET studies from other 
psychiatric research is the injection of radioactivity into the research subjects. Each PET 
examination can roughly be translated to the radiation dose that a person would get from the 
background radiation for 18 months living in Sweden. Although the risk of causing any 
disease is considered minimal, it is impossible to escape the fact that the radiation causes 
some measure of harm. However, currently PET is the only effective way to quantify a given 
protein in the brain in vivo. I can see no viable option to answer the research questions we are 
addressing in the present studies. Given the limited knowledge of MDD, the suffering the 
disorder imposes on the affected individuals along with the economic burden to society, my 
belief is that the risks are acceptable. 
The PET examination itself is not entirely pleasant. The research subjects must lay still for 
approximately 100 minutes with the head inside a narrow tunnel. The plaster helmet we use 
to minimize head movement in the camera can sometimes cause discomfort but is generally 
well tolerated. Some pain arises from catheterization of a peripheral vein used for injection of 
radioligand. The full procedure is described in detail to the research subjects prior to them 
signing the informed consent. 
Patients and healthy controls receive a cash payment of SEK 1000–3000 for participation. 
Other potential benefits include undergoing an MR examination that is reviewed by a 
neuroradiologist. This, however, is a double-edged sword. Though it is possible to detect 
disease at an early stage, it is not uncommon to find abnormalities that are clinically 
unimportant but can cause psychological distress for the subject and possibly lead to 
unnecessary treatments. During the recruitment for study III, we had a case where signs of 
previous inflammation in the brain were observed. It may have been caused by some 
nonspecific disease many years ago that the patient did not know of and that would never 
have caused any problems, but it may also have been multiple sclerosis where the patient's 
prognosis can be improved by discovering the disease early. 
In study III, we preregistered the analysis plan. Preregistration reduces the researcher’s 
degrees of freedom which can lower the risk of false positive findings, which is an inherent 
ethical good.  
Looking at the potential impact the studies might have in society, I cannot see any major 
ethical pitfalls. Politically, the field we investigate is rather uncontroversial (in my opinion). 
If we find that the 5-HTT, or D2R, play a role in depression, it is unlikely to directly change 
any treatment standards or put the concept of depression in a drastically different light. Rather 
it will be another building block in the effort to close in on an understanding of what goes on 
in the brain during depression. 
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7 FUTURE PERSPECTIVES 
 
Regarding study I, the fact that in many cortical regions no decrease was observed in BPND 
after administration of a competitor is interesting and warrants further investigation. The 
explanation we propose for this phenomenon is that most of the BPND in cortex reflect a bias 
caused by lower CND in the reference tissue compared with the target regions. If this is the 
case then it could be specific to [
11
C]raclopride, but it is also possible that it is connected to a 
fundamental difference in the anatomy of cerebellum compared with cerebral regions. E.g., 
the resolution of today’s PET systems is at best about 2mm, whereas the average thickness of 
the cerebellar cortex is about 1mm
114
.  It is thus unavoidable that when cerebellar cortex is 
used as a reference region, the voxels will contain some amount of white matter and some 
CSF. The cerebral cortex is about 2.5mm and profoundly less convoluted
114
. Even if CND is 
exactly the same in cerebellar and cerebral cortical tissue, it is unlikely that the CND 
contribution of radioactivity measured with PET in e.g., dorsolateral prefrontal cortex, will be 
exactly the same as that in a cerebellar reference region. This is trivially true for any given 
individual, but it is likely true also on group level. If this is the cause of the results observed 
in study 1, it is possible that a similar effect is present for other radioligands where 
cerebellum is used as a reference tissue. In high binding regions, a small discrepancy between 
CND in target and reference region has little consequence, but it is not uncommon that 
radioligands are validated in high binding regions, but later low binding regions are reported 
in the literature. One way to test if a general effect exists is to examine occupancy datasets 
applying other radioligands, comparing low and high binding regions for a pattern like what 
we observe in study I.  
Out of the four studies contained in this thesis I think study III is the most important to 
continue to build on. The observed increase in 5-HTT availability in MDD patients following 
CBT can be interpreted in many ways and could have important implications. It has been 
suggested that the main role of the cerebral serotonin system is to enhance adaptive responses 
to adverse conditions, mainly through improving an individual’s resilience to stress
3,72
. When 
applied to psychiatric disorders, serotonin transmission could then be hypothesized to be part 
of an innate coping system in the brain, reducing the risk of long-lasting stress induced 
symptoms, and, by extension, psychiatric conditions. Under this theory, the findings in study 
III could be explained as that 5-HTT was relatively low in response to the stress underlying 
the depression. As the depressive symptoms were alleviated following therapy, the coping 
system was no longer needed and 5-HTT levels increased towards premorbid levels. If this 
theory of serotonin mediated coping is verified, it could shift how the serotonin system is 
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